Amprion Patent Information

Amprion continues to build its intellectual property surrounding the company's proprietary methodology for highly sensitive detection of misfolded proteins and amyloid-like aggregates. Recently, fundamental patents have issued in key geographies which expand our extensive coverage in the EU and UK. The issued patents apply broadly to the methodology known alternatively as Seed Amplification Assay (SAA), Protein Misfolding Cyclic Amplification (PMCA) or Real Time Quaking induced Conversion (RT-QuiC).

Amprion’s owned or exclusively-licensed alpha-synuclein portfolio is particularly extensive. The portfolio currently includes multiple allowed and/or issued patents in the United States, EU, Japan, UK, Korea, Singapore, Australia, Israel, Canada, and Mexico, with applications pending in India, China, Hong Kong, and Brazil. Amprion also has an issued US patent and pending applications worldwide directed to Amprion’s proprietary alpha-synuclein SAA substrate plus other key components needed for robust, reliable and reproducible performance of the technology.”

Download Spec Sheet

SYNTap Biomarker CSF Test performance characteristics.

Breaking

FDA Breakthrough

The U.S. FDA awarded Amprion Breakthrough Device Designation. 

Amprion Science

We help accelerate precision medicine through biomarker testing.

Russ walking through Amprion Lab

Molecular Testing Leads to Precision Medicine

“Neurodegenerative diseases affect individuals differently. For instance, ten patients can have ten different biomarker profiles. In addition, symptoms often overlap, leading to diagnostic challenges.

The SYNTap Biomarker CSF Test offers physicians a molecular tool to greatly improve diagnostic accuracy. Our goal is to develop precision medicine through biomarker testing.”

~ CEO, Russ Lebovitz, M.D./Ph.D

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.


Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.